## Tyenne® (tocilizumab-aazg) – New biosimilar formulation launch

- On July 2, 2024, Fresenius Kabi announced the launch of Tyenne (tocilizumab-aazg) *subcutaneous* formulation, a biosimilar to Roche's Actemra (tocilizumab).
    - Fresenius Kabi's Tyenne intravenous formulation launched on April 15, 2024.
    - In addition, Biogen's Tofidence™ (tocilizumab-bavi) intravenous formulation launched on May 6, 2024.
- Tyenne, Tofidence and Actemra share the following indication in adult patients:
    - Moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.
- Tyenne and Actemra share the following indication in adult patients:
    - Giant cell arteritis.
- Tyenne, Tofidence and Actemra share the following indications in patients 2 years of age and older:
    - Active polyarticular juvenile idiopathic arthritis
    - Active systemic juvenile idiopathic arthritis.
- Actemra is also indicated for the following:
    - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease
    - Chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older
    - Coronavirus disease 2019 in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
- Like Actemra and Tofidence, Tyenne carries a boxed warning for risk of serious infections.